haloperidol has been researched along with norfluoxetine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Sen, S; Sinha, N | 1 |
| Bennis, K; Ducki, S; Lesage, F; Vivier, D | 1 |
| Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Wilson, AA | 1 |
1 review(s) available for haloperidol and norfluoxetine
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pain; Potassium Channels, Tandem Pore Domain; Structure-Activity Relationship | 2016 |
3 other study(ies) available for haloperidol and norfluoxetine
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
[11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Topics: Adrenergic Uptake Inhibitors; Animals; Benzylamines; Brain; Carrier Proteins; Cats; Citalopram; Dopamine Antagonists; Fluoxetine; Haloperidol; Maprotiline; Membrane Glycoproteins; Membrane Transport Proteins; Monoamine Oxidase Inhibitors; Nerve Tissue Proteins; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tissue Distribution; Tomography, Emission-Computed; Tranylcypromine | 2003 |